The HLA locus and multiple sclerosis in Spain. Role in disease susceptibility, clinical course and response to interferon-β
Pablo Villoslada(Hospital Del Mar), Jorge R. Oksenberg(University of California, San Francisco), Pilar Casquero, Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya), Mar Tintoré(Vall d'Hebron Hospital Universitari), Jordi Río(Universitat Autònoma de Barcelona), Lisa F. Barcellos(University of California, San Francisco), Stephen L. Hauser(University of California, San Francisco), Sergio E. Baranzini(University of California, San Francisco), Ann B. Begovich, Jaume Sastre‐Garriga(Universitat Autònoma de Barcelona)
Cited by 75
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k